Biomarcadores en líquido cefalorraquídeo de pacientes con enfermedad de Alzheimer prodrómica
- Monge Argilés, José Antonio
- Muñoz Ruiz, Carlos
- Sánchez Payá, José
- Montoya Gutiérrez, Francisco Javier
- Rodríguez Borja, Enrique
- Leiva Santana, Carlos
ISSN: 1137-1242
Ano de publicación: 2011
Número: 49
Páxinas: 19-25
Tipo: Artigo
Outras publicacións en: Alzheimer: Realidades e investigación en demencia
Resumo
Introduction: The prodromal Alzheimer�Ls disease (AD) is a new concept that include an amnesic mild cognitive impairment (MCIa) and alterations in some complementary tests. Objective: To test the presence of alterations in the cerebrospinal fluid (CSF) biomarkers in our MCI-a patients who developed AD in the first year after the lumbar puncture. Method: 24 control subjects and 36 MCI-a patients were included from the local hospital memory clinic. Using INNO-BIA Alzbio-3 reagents from Innogenetics, we quantified CSF A�À1-42, T-tau and P-tau181p proteins, and calculated the ratios T-tau / A�À1-42 y P-tau 181p / A�À1-42. This project was approved by the local Ethical Committee. Results: One year after the lumbar puncture, 14 MCI patients (38%) developed AD. These patients showed lower A�À1-42 protein levels (285.37 �} 73.36 vs. 365.21 �} 112.53 pg/ml, p < 0.02) and higher T-tau protein (88.3 �} 40.82 vs. 53.21 �} 23.38 pg/ml, p < 0.002), P-tau 181p protein (66.44 �} 23.87 vs. 31.25 �} 13.74 pg/ml, p< 0.02 ), T-tau / A�À1-42 ratio (0.34 �} 0.19 vs. 0.15 �} 0.08, p < 0.001 ) and P-tau 181p / A�À1-42 ratio (0.25 �} 0.12 vs. 0.09 �} 0.06, p < 0.0001) than the control subjects. Conclusion: In our experience, as the recent literature, it exist the very clear alterations of CSF biomarkers in patients with prodromal AD.